compounded semaglutide going away Compound versions of GLP-1 drugs for weight loss halted by FDA Not my most flattering photos.

The cardiovascular protective mechanisms of GLP-1 receptor agonists are thought to include: Improved glycaemic control , reducing endothelial dysfunction associated with hyperglycaemia Weight reduction , decreasing metabolic stress and inflammation Blood pressure lowering , potentially through effects on fluid balance and vascular function Favourable lipid profile changes , including modest reductions in LDL cholesterol and triglycerides Anti-inflammatory effects , reducing systemic markers of inflammation such as C-reactive protein Regulatory bodies including the MHRA and EMA have not identified thrombotic events as a specific safety concern with GLP-1 receptor agonists

Beyond GLP-1s: Withings Health Solutions unveils best practices for obesity care management programs In partnership with obesity care leaders, Withings Health Solutions redefines obesity care with connected devices to sustain engagement and improve outcomes in the GLP-1 era

doi: 10.1038/nrdp.2016.43

Biomarkers of inflammation, endothelial function, and genotoxicity These outcomes were measured using a high-sensitivity Interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), Interleukin-10 (IL-10), human soluble intercellular adhesion molecule 1 (sICAM1), and soluble vascular cell adhesion molecule 1 (sVCAM1) ELISA kits (Invitrogen, Thermo-Scientific Inc., Waltham, MA), and high-sensitivity human C-reactive protein Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA)